Regeneron Pharmaceuticals (REGN) to Release Quarterly Earnings on Wednesday

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) is scheduled to be issuing its quarterly earnings data before the market opens on Wednesday, May 4th. Analysts expect the company to announce earnings of $9.78 per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) last issued its earnings results on Friday, February 4th. The biopharmaceutical company reported $23.72 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $18.49 by $5.23. Regeneron Pharmaceuticals had a return on equity of 55.11% and a net margin of 50.24%. The business had revenue of $4.95 billion during the quarter, compared to analysts’ expectations of $4.49 billion. During the same period in the prior year, the firm posted $8.72 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 104.4% compared to the same quarter last year. On average, analysts expect Regeneron Pharmaceuticals to post $45 EPS for the current fiscal year and $46 EPS for the next fiscal year.

REGN stock opened at $674.82 on Wednesday. The business has a fifty day moving average price of $671.28 and a 200 day moving average price of $638.08. Regeneron Pharmaceuticals has a fifty-two week low of $478.40 and a fifty-two week high of $747.42. The stock has a market capitalization of $72.57 billion, a price-to-earnings ratio of 9.36, a P/E/G ratio of 1.22 and a beta of 0.21. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.56 and a quick ratio of 3.07.

In other Regeneron Pharmaceuticals news, CFO Robert E. Landry sold 83 shares of the stock in a transaction on Thursday, March 17th. The shares were sold at an average price of $686.00, for a total transaction of $56,938.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, February 1st. The stock was sold at an average price of $607.46, for a total transaction of $607,460.00. The disclosure for this sale can be found here. Insiders have sold 44,459 shares of company stock valued at $30,177,797 over the last three months. 11.84% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Integrated Wealth Concepts LLC grew its position in Regeneron Pharmaceuticals by 3.5% during the 4th quarter. Integrated Wealth Concepts LLC now owns 564 shares of the biopharmaceutical company’s stock worth $356,000 after purchasing an additional 19 shares during the last quarter. Harbour Investments Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 12.8% in the 4th quarter. Harbour Investments Inc. now owns 405 shares of the biopharmaceutical company’s stock valued at $256,000 after acquiring an additional 46 shares during the last quarter. Peapack Gladstone Financial Corp boosted its holdings in shares of Regeneron Pharmaceuticals by 5.3% in the 4th quarter. Peapack Gladstone Financial Corp now owns 2,241 shares of the biopharmaceutical company’s stock valued at $1,415,000 after acquiring an additional 112 shares during the last quarter. Zullo Investment Group Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $75,000. Finally, EverSource Wealth Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $96,000. Institutional investors own 82.97% of the company’s stock.

REGN has been the topic of several recent analyst reports. Cowen lifted their target price on Regeneron Pharmaceuticals from $640.00 to $645.00 in a report on Wednesday, April 20th. Bank of America downgraded Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and lowered their target price for the company from $675.00 to $575.00 in a research report on Wednesday, January 5th. Truist Financial lowered their price target on Regeneron Pharmaceuticals from $754.00 to $728.00 and set a “buy” rating on the stock in a research report on Tuesday, February 8th. Cowen boosted their price objective on Regeneron Pharmaceuticals from $640.00 to $645.00 in a report on Wednesday, April 20th. Finally, Zacks Investment Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $694.00 price target for the company in a research note on Monday, January 10th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $724.63.

Regeneron Pharmaceuticals Company Profile (Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Articles

Earnings History for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.